Literature DB >> 30842609

PAX5 biallelic genomic alterations define a novel subgroup of B-cell precursor acute lymphoblastic leukemia.

Lorenz Bastian1,2,3,4,5, Michael P Schroeder1, Cornelia Eckert3,4,6, Cornelia Schlee1, Jutta Ortiz Tanchez1, Sebastian Kämpf1, Dimitrios L Wagner2,7,8, Veronika Schulze1, Konstandina Isaakidis1, Juan Lázaro-Navarro1,3,4, Sonja Hänzelmann5, Alva Rani James1,3,4, Arif Ekici9, Thomas Burmeister1, Stefan Schwartz1, Martin Schrappe10, Martin Horstmann11, Sebastian Vosberg3,4,12, Stefan Krebs13, Helmut Blum13, Jochen Hecht14,15, Philipp A Greif3,4,12, Michael A Rieger3,4,16, Monika Brüggemann5, Nicola Gökbuget3,4,16, Martin Neumann1,3,4,5, Claudia D Baldus17,18,19,20,21.   

Abstract

Chromosomal rearrangements and specific aneuploidy patterns are initiating events and define subgroups in B-cell precursor acute lymphoblastic leukemia (BCP-ALL). Here we analyzed 250 BCP-ALL cases and identified a novel subgroup ('PAX5-plus', n = 19) by distinct DNA methylation and gene expression profiles. All patients in this subgroup harbored mutations in the B-lineage transcription factor PAX5, with p.P80R as hotspot. Mutations either affected two independent codons, consistent with compound heterozygosity, or suffered LOH predominantly through chromosome 9p aberrations. These biallelic events resulted in disruption of PAX5 transcriptional programs regulating B-cell differentiation and tumor suppressor functions. Homozygous CDKN2A/B deletions and RAS-activating hotspot mutations were highly enriched as cooperating events in the genomic profile of PAX5-plus ALL. Together, this defined a specific pattern of triple alterations, exclusive to the novel subgroup. PAX5-plus ALL was observed in pediatric and adult patients. Although restricted by the limited sample size, a tendency for more favorable clinical outcome was observed, with 10 of 12 adult PAX5-plus patients achieving long-term survival. PAX5-plus represents the first BCP-ALL subgroup defined by sequence alterations in contrast to gross chromosomal events and exemplifies how deregulated differentiation (PAX5), impaired cell cycle control (CDKN2A/B) and sustained proliferative signaling (RAS) cooperatively drive leukemogenesis.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30842609     DOI: 10.1038/s41375-019-0430-z

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  17 in total

Review 1.  Emerging molecular subtypes and therapeutic targets in B-cell precursor acute lymphoblastic leukemia.

Authors:  Jianfeng Li; Yuting Dai; Liang Wu; Ming Zhang; Wen Ouyang; Jinyan Huang; Saijuan Chen
Journal:  Front Med       Date:  2021-01-05       Impact factor: 4.592

Review 2.  Molecular markers in ALL: Clinical implications.

Authors:  Shunsuke Kimura; Charles G Mullighan
Journal:  Best Pract Res Clin Haematol       Date:  2020-06-07       Impact factor: 3.020

3.  IRF4 deficiency vulnerates B-cell progeny for leukemogenesis via somatically acquired Jak3 mutations conferring IL-7 hypersensitivity.

Authors:  Dennis Das Gupta; Christoph Paul; Nadine Samel; Maria Bieringer; Daniel Staudenraus; Federico Marini; Hartmann Raifer; Lisa Menke; Lea Hansal; Bärbel Camara; Edith Roth; Patrick Daum; Michael Wanzel; Marco Mernberger; Andrea Nist; Uta-Maria Bauer; Frederik Helmprobst; Malte Buchholz; Katrin Roth; Lorenz Bastian; Alina M Hartmann; Claudia Baldus; Koichi Ikuta; Andreas Neubauer; Andreas Burchert; Hans-Martin Jäck; Matthias Klein; Tobias Bopp; Thorsten Stiewe; Axel Pagenstecher; Michael Lohoff
Journal:  Cell Death Differ       Date:  2022-04-22       Impact factor: 15.828

4.  MRD in adult Ph/BCR-ABL-negative ALL: how best to eradicate?

Authors:  Nicola Gökbuget
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2021-12-10

5.  The genomic landscape of pediatric acute lymphoblastic leukemia.

Authors:  Samuel W Brady; Kathryn G Roberts; Zhaohui Gu; Lei Shi; Stanley Pounds; Deqing Pei; Cheng Cheng; Yunfeng Dai; Meenakshi Devidas; Chunxu Qu; Ashley N Hill; Debbie Payne-Turner; Xiaotu Ma; Ilaria Iacobucci; Pradyuamna Baviskar; Lei Wei; Sasi Arunachalam; Kohei Hagiwara; Yanling Liu; Diane A Flasch; Yu Liu; Matthew Parker; Xiaolong Chen; Abdelrahman H Elsayed; Omkar Pathak; Yongjin Li; Yiping Fan; J Robert Michael; Michael Rusch; Mark R Wilkinson; Scott Foy; Dale J Hedges; Scott Newman; Xin Zhou; Jian Wang; Colleen Reilly; Edgar Sioson; Stephen V Rice; Victor Pastor Loyola; Gang Wu; Evadnie Rampersaud; Shalini C Reshmi; Julie Gastier-Foster; Jaime M Guidry Auvil; Patee Gesuwan; Malcolm A Smith; Naomi Winick; Andrew J Carroll; Nyla A Heerema; Richard C Harvey; Cheryl L Willman; Eric Larsen; Elizabeth A Raetz; Michael J Borowitz; Brent L Wood; William L Carroll; Patrick A Zweidler-McKay; Karen R Rabin; Leonard A Mattano; Kelly W Maloney; Stuart S Winter; Michael J Burke; Wanda Salzer; Kimberly P Dunsmore; Anne L Angiolillo; Kristine R Crews; James R Downing; Sima Jeha; Ching-Hon Pui; William E Evans; Jun J Yang; Mary V Relling; Daniela S Gerhard; Mignon L Loh; Stephen P Hunger; Jinghui Zhang; Charles G Mullighan
Journal:  Nat Genet       Date:  2022-09-01       Impact factor: 41.307

6.  UBTF::ATXN7L3 gene fusion defines novel B cell precursor ALL subtype with CDX2 expression and need for intensified treatment.

Authors:  Lorenz Bastian; Alina M Hartmann; Thomas Beder; Sonja Hänzelmann; Jan Kässens; Miriam Bultmann; Marc P Hoeppner; Sören Franzenburg; Michael Wittig; Andre Franke; Inga Nagel; Malte Spielmann; Niklas Reimer; Hauke Busch; Stefan Schwartz; Björn Steffen; Andreas Viardot; Konstanze Döhner; Mustafa Kondakci; Gerald Wulf; Knut Wendelin; Andrea Renzelmann; Alexander Kiani; Heiko Trautmann; Martin Neumann; Nicola Gökbuget; Monika Brüggemann; Claudia D Baldus
Journal:  Leukemia       Date:  2022-04-09       Impact factor: 12.883

7.  Establishment and characterization of a novel childhood acute lymphoblastic leukemia cell line, HXEX-ALL1, with chromosome 9p and 17p deletions.

Authors:  Yiping Zhu; Rong Yang; Ju Gao; Yanle Zhang; Ge Zhang; Ling Gu
Journal:  Cancer Cell Int       Date:  2019-04-29       Impact factor: 5.722

8.  Frequency and prognostic impact of PAX5 p.P80R in pediatric acute lymphoblastic leukemia patients treated on an AIEOP-BFM acute lymphoblastic leukemia protocol.

Authors:  Mareike Jung; Maximilian Schieck; Winfried Hofmann; Marcel Tauscher; Jana Lentes; Anke Bergmann; Marie Stelter; Anja Möricke; Julia Alten; Brigitte Schlegelberger; Martin Schrappe; Martin Zimmermann; Martin Stanulla; Gunnar Cario; Doris Steinemann
Journal:  Genes Chromosomes Cancer       Date:  2020-07-07       Impact factor: 5.006

9.  The hematopoietic stem cell marker VNN2 is associated with chemoresistance in pediatric B-cell precursor ALL.

Authors:  Beat Bornhauser; Gunnar Cario; Anna Rinaldi; Thomas Risch; Virginia Rodriguez Martinez; Moritz Schütte; Hans-Jörg Warnatz; Nastassja Scheidegger; Paulina Mirkowska; Martina Temperli; Claudia Möller; Angela Schumich; Michael Dworzak; Andishe Attarbaschi; Monika Brüggemann; Mathias Ritgen; Ester Mejstrikova; Andreas Hofmann; Barbara Buldini; Pamela Scarparo; Giuseppe Basso; Oscar Maglia; Giuseppe Gaipa; Tessa-Lara Skoblyn; Geertruij Te Kronnie; Elena Vendramini; Renate Panzer-Grümayer; Malwine Jeanette Barz; Blerim Marovca; Mathias Hauri-Hohl; Felix Niggli; Cornelia Eckert; Martin Schrappe; Martin Stanulla; Martin Zimmermann; Bernd Wollscheid; Marie-Laure Yaspo; Jean-Pierre Bourquin
Journal:  Blood Adv       Date:  2020-09-08

Review 10.  The Biology of B-Progenitor Acute Lymphoblastic Leukemia.

Authors:  Kathryn G Roberts; Charles G Mullighan
Journal:  Cold Spring Harb Perspect Med       Date:  2020-07-01       Impact factor: 5.159

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.